|
|
News Breaks | | | | December 14, 2012 | | 14:08 EDT |  | ARIA | ARIAD slumps after FDA requires warning on newly approved drug
ARIAD Pharmaceuticals (ARIA) is retreating after the company said that the FDA had approved the company's leukemia treatment, but will require it to include a warning on the drug's box. The warning will state that the drug, Iclusig, can cause blood clots and liver toxicity, ARIAD disclosed earlier today. In a note to investors, Citigroup wrote that the Street had not expected the company to be forced to issue such a warning. The firm, however, views the FDA's decision to grant accelerated approval to the drug as positive and it maintains a Buy rating on the stock. In mid-afternoon trading, ARIAD fell $2.33, or 9.76%, to $21.55. | |
|
News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. |
|
|
| May 20, 2013 | | 07:34 EDT |  | ARIA | UBS to host a conference
 Subscribe for More Information | | | May 17, 2013 | | 08:22 EDT |  | ARIA | ARIAD shares should be bought on weakness, says BMO Capital
Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | ARIA | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | |
|
|
|
|
|
|
